The landscape of ADC development is also expanding to include novel targets beyond HER2, such as CEACAM5, Claudin-2, and DDR1, broadening the applicability of ADCs to various BC subtypes [13,14,15]. The gene discussed is ERBB2; the disease is breast cancer.